Cargando…
Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry)
INTRODUCTION: Given an increasing use of dipeptidyl peptidase-4 (DPP-4) inhibitors to treat patients with type 2 diabetes mellitus in the real-world setting, we conducted a prospective observational study (Japan-based Clinical Research Network for Diabetes Registry: J-BRAND Registry) to elucidate th...
Autores principales: | Ueki, Kohjiro, Tanizawa, Yukio, Nakamura, Jiro, Yamada, Yuichiro, Inagaki, Nobuya, Watada, Hirotaka, Shimomura, Iichiro, Nishimura, Rimei, Miyoshi, Hideaki, Abiko, Atsuko, Katagiri, Hideki, Hayashi, Michio, Shimada, Akira, Naruse, Keiko, Fujimoto, Shimpei, Fujiwara, Masazumi, Shikata, Kenichi, Okada, Yosuke, Araki, Eiichi, Yamazaki, Tsutomu, Kadowaki, Takashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812112/ https://www.ncbi.nlm.nih.gov/pubmed/33441417 http://dx.doi.org/10.1136/bmjdrc-2020-001787 |
Ejemplares similares
-
Protocol for a large-scale prospective observational study with alogliptin in patients with type 2 diabetes: J-BRAND Registry
por: Inagaki, Nobuya, et al.
Publicado: (2014) -
Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001–2010: Report of the Committee on Causes of Death in Diabetes Mellitus
por: Nakamura, Jiro, et al.
Publicado: (2017) -
Evaluation of the Effect of Alogliptin on Tissue Characteristics of the Carotid Wall: Subanalysis of the SPEAD-A Trial
por: Irie, Yoko, et al.
Publicado: (2018) -
Alogliptin: a new addition to the class of DPP-4 inhibitors
por: Andukuri, Radha, et al.
Publicado: (2009) -
Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39:139–148
por: Mita, Tomoya, et al.
Publicado: (2017)